Detail akcie Xenetic Bioscs Rg online

Business Summary: Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Xenetic Biosciences Inc revenues increased 19% to $2.2M. Net loss decreased 28% to $2.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Salaries and wages decrease from $562K (expense) to $0K, Selling and general decrease of 19% to $2.1M (expense).